NASDAQ:SLN Silence Therapeutics Q4 2025 Earnings Report $13.72 -0.25 (-1.79%) Closing price 04:00 PM EasternExtended Trading$13.69 -0.03 (-0.22%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Silence Therapeutics EPS ResultsActual EPS-$0.25Consensus EPS -$0.32Beat/MissBeat by +$0.07One Year Ago EPSN/ASilence Therapeutics Revenue ResultsActual Revenue$0.03 millionExpected Revenue$2.19 millionBeat/MissMissed by -$2.16 millionYoY Revenue GrowthN/ASilence Therapeutics Announcement DetailsQuarterQ4 2025Date3/6/2026TimeBefore Market OpensConference Call DateThursday, March 5, 2026Conference Call Time7:30AM ETConference Call ResourcesPress Release (6-K)Annual Report (10-K)Annual ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(10-K)Annual report Silence Therapeutics Earnings HeadlinesSilence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs4 hours ago | businesswire.comAnalysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)August 12 at 6:33 PM | theglobeandmail.comAI insiders stockpile guns, gold & gas masksKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift in the AI market is approaching, and time is short to prepare. Kaplan points to August 31st as a key turning point for AI investing. He argues the next phase will separate winners from losers, and reveals what he's watching instead of big names like Nvidia.August 14 at 1:00 AM | TradeSmith (Ad)Silence Therapeutics (SLN) Receives a Buy from Morgan StanleyAugust 12 at 6:33 PM | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)August 12 at 8:02 AM | theglobeandmail.comSilence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public OfferingAugust 11 at 11:20 PM | businesswire.comSee More Silence Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silence Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silence Therapeutics and other key companies, straight to your email. Email Address About Silence TherapeuticsSilence Therapeutics (NASDAQ:SLN) plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities. The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism. Both programs have advanced through early clinical stages, generating proof-of-concept data. Silence also maintains a portfolio of preclinical research programs targeting liver-related diseases, while exploring strategic collaborations to broaden the reach of its RNAi platform across multiple therapeutic areas. Founded in the United Kingdom and headquartered in London, Silence Therapeutics operates research and development facilities in Europe and the United States. The company has navigated the evolving RNA therapeutics landscape since the early 2000s, transitioning from discovery research into clinical development. Under the leadership of Chief Executive Officer Eric M. Rose, Silence continues to advance its pipeline with the objective of delivering novel RNAi medicines to patients with high-unmet medical needs worldwide.View Silence Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
